Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: PageGroup Slumps After Profit Warning

Wed, 10th Jul 2019 10:40

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - LOSERS----------Micro Focus International, down 6.5%. Shares in the software company continued to slide after it reported a drop in revenue and maintained its annual guidance on Tuesday. Micro Focus on Tuesday also said its high-profile acquisition of Hewlett Packard's software business was still proving difficult to integrate into its existing operations, stressing it was a "complex and significant progamme of work". The stock is down 10% since the start of the week. ----------Ashtead Group, down 1.0%. Morgan Stanley cut the equipment rentals firm to Equal Weight from Overweight. ----------FTSE 250 - WINNERS----------JD Wetherspoon, up 3.2%. The pub chain said sales were higher in the year so far and its expectations for its current financial year are unchanged. Wetherspoon said its like-for-like sale were up 6.9% for the ten weeks to July 7, with total sales up 6.6% for the same period. Year-to-date, like-for-like sales were up 6.7% while total sales rose 7.4%. The company's financial year ends on July 28, on which date the company expects to have net debt of around GBP745 million. Since its financial year began, JD Wetherspoon has opened five new pubs and disposed of another nine, with no more openings planned for its current financial year. Chair Tim Martin said that "the company's expectation for our annual results is unchanged for the current financial year".----------Playtech, up 3.0%. JPMorgan started coverage on the gambling software provider with an Overweight rating. ----------FTSE 250 - LOSERS----------PageGroup, down 15%. The recruiter said it achieved gross profit growth in its first half but expects an annual operating profit at the lower end of market expectations due to "challenging" macroeconomic conditions. Page said total gross profit for the first half of 2019 was GBP433.5 million, a 9.5% increase as reported and also 9.5% at constant currency. For the second quarter alone, gross profit was GBP224.6 million, a 7.9% rise over its GBP208.2 million gross profit the year before and a 7.4% rise at constant currency. In both the second half and the second quarter, gross profit increased most sharply in the Americas, with reported growth of 21% to GBP69.1 million from GBP57.3 million in the first half and 19% to GBP36.9 million from GBP30.9 million in the second quarter. Europe, the Middle East & Africa - which accounted for 49% of the group's profit in the first half and 48% in the second quarter - also performed well with half-year reported profit growth of 9.3% to GBP213.1 million from GBP194.9 million. Despite this growth, 2019 operating profit is expected to be at the low end of market expectations due to a difficult economic environment, Page said. ----------Hays, down 6.0%. UBS cut the recruiter to Neutral from Buy, and it also suffered a read-across from PageGroup. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Redx Pharma. Shares in the cancer and fibrosis drug discovery company doubled to 14 pence after it signed a definitive agreement with Nasdaq-listed Jazz Pharmaceuticals to sell its pan-RAF inhibitor programme. As part of the agreement, Redx will receive an upfront payment of USD3.5 million in cash but is eligible to receive up to USD203 million in development, regulatory and commercial milestone payments. The next milestone is the initiation of investigational new drug studies, followed by an IND submission to the US Food & Drug Administration. Redx also is eligible for incremental tiered royalties in "mid-single digit" percentage, based on any future net sales. ----------Xeros Technology, up 32%. The water saving and effluent reduction technology firm said its patent application for microfibre filters in domestic washing machines has been published. The patent application for the device, trademarked XFiltra, can now be licenced by domestic washing machine manufacturers. The application was published by the World Intellectual Property Organization. Xeros noted that the washing of clothes made from synthetic fibres is "the single biggest source of primary microplastics released into the oceans every year", with up to 700,000 microfibres released into the environment in just one domestic wash cycle.----------OTHER MAIN MARKET AND AIM - LOSERS----------Superdry, down 0.5%. The troubled fashion retailer reduced its annual payout after reporting a swing to loss in its most recently ended financial year. The company chopped its final dividend to 2.2 pence a share from 21.3p last year, taking the full-year payout to 11.5p per share, little more than a third the 31.2p paid in its financial 2018. Superdry said its revenue for the 52 weeks to April 27 was GBP871.7 million, broadly flat compared to GBP872.0 million reported for the same period a year ago, due to "a difficult retail climate". Superdry explained that its first half performance benefited from discounting and space growth, but it saw poor performance in the second half across all channels. The company posted a loss of GBP85.4 million, compared to GBP65.3 million profit reported a year earlier, as its underlying operating margin declined by 600 basis points to 5.5% from 11.5% the year before. Despite its struggles, Jefferies started coverage on Superdry with a Buy rating.----------

More News
11 Mar 2020 10:23

Redx Pharma Optimistic As Loss Narrows And Cancer Trial Progresses

Redx Pharma Optimistic As Loss Narrows And Cancer Trial Progresses

Read more
28 Feb 2020 18:47

UPDATE: Redx Pharma To Get GBP26 Million Injection Amid No Yesod Bid

UPDATE: Redx Pharma To Get GBP26 Million Injection Amid No Yesod Bid

Read more
28 Feb 2020 18:08

No Redx Pharma Takeover As Yesod Opts Not To Make Offer

No Redx Pharma Takeover As Yesod Opts Not To Make Offer

Read more
14 Feb 2020 17:11

UK Regulator Extends Deadline For Possible Redx Pharma Cash Offer

UK Regulator Extends Deadline For Possible Redx Pharma Cash Offer

Read more
28 Jan 2020 14:15

UK Regulator Extends Deadline For Possible Redx Pharma Cash Offer

UK Regulator Extends Deadline For Possible Redx Pharma Cash Offer

Read more
24 Jan 2020 11:51

Moulton Goodies Raises Stake In Redx Pharma To 42% From 18%

Moulton Goodies Raises Stake In Redx Pharma To 42% From 18%

Read more
9 Jan 2020 16:02

Redx Pharma nominates next drug development candidate

(Sharecast News) - Drug discovery and development company Redx Pharma announced the nomination of RXC007 as its next drug development candidate for the treatment of fibrosis on Thursday.

Read more
9 Jan 2020 11:17

Redx Pharma Nominates Another Anti-Fibrosis Drug Candidate

Redx Pharma Nominates Another Anti-Fibrosis Drug Candidate

Read more
31 Dec 2019 10:34

UK WINNERS & LOSERS SUMMARY: Redx Surges On Potential Takeover Offer

UK WINNERS & LOSERS SUMMARY: Redx Surges On Potential Takeover Offer

Read more
31 Dec 2019 09:12

Redx Pharma Shares Soar On Discussions Over Possible Takeover Offer

Redx Pharma Shares Soar On Discussions Over Possible Takeover Offer

Read more
31 Dec 2019 08:51

LONDON MARKET OPEN: Stocks Start Mostly Lower Amid Profit Taking

LONDON MARKET OPEN: Stocks Start Mostly Lower Amid Profit Taking

Read more
19 Nov 2019 12:29

Redx collaboration with MDC awarded Innovate UK funding

(Sharecast News) - Redx Pharma announced on Tuesday that Innovate UK has awarded biomedical catalyst funding to Redx and Medicines Discovery Catapult (MCD).

Read more
19 Nov 2019 11:53

Redx Pharma Secures Funding To Develop Lung Condition Therapies

Redx Pharma Secures Funding To Develop Lung Condition Therapies

Read more
19 Aug 2019 10:22

Redx Pharma Gets Approval To Escalate Dose In RXC004 Study

(Alliance News) - Redx Pharma PLC on Monday said it has successfully completed dosing of the first cohort of patients in its ongoing phase 1/2 study with RXC004.RXC004 is an oral porcupine

Read more
19 Aug 2019 09:43

Redx Pharma gets green light to escalate dose in RXC004 study

(Sharecast News) - Drug discovery and development company Redx Pharma has successfully completed dosing of the first cohort of patients in its ongoing phase 1 and 2 study with 'RXC004', it announced on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.